YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Leadership shift puts IDEAYA Biosciences in focus IDEAYA Biosciences (IDYA) has moved Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective 28 September 2026. The change puts its R&D leadership f…
[mrna Cancer Vaccine] wildpixel/iStock via Getty Images INVESTORS SHOULD KNOW: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma into a broader test across harder-to-treat solid tumors. The…
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion o…
On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Ph…
[Ozempic Insulin injection pen] CR/iStock via Getty Images INVESTORS SHOULD KNOW: The obesity drug market is undergoing a structural shift, moving beyond the initial injectable GLP-1 franchise. Now, the industry is moving toward a broader…
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on Septem…
Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences…
Global Phase 3 trial will evaluate the darovasertib and crizotinib combination in primary uveal melanoma patients with increased risk of metastasis following completion of local therapy OptimUM-11 expands development of darovasertib across…
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Inv…
Based on FDA Type C meeting, targeting to initiate a randomized Phase 3 registrational trial for IDE849 monotherapy by year-end 2026 in ES-SCLC, with ORR by BICR as the primary endpoint for potential accelerated approval and median OS as t…
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-muta…
IDEAYA Biosciences recently reported a second-quarter 2026 net loss of US$112.45 million, or US$1.22 per basic and diluted share, while also disclosing a wider six‑month loss versus the prior year. In parallel, IDEAYA advanced its precisio…
Registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma (mUM) met its primary endpoint; new drug application (NDA) filing is underway under the real-time oncology review program (RTOR) with completion e…
SOUTH SAN FRANCISCO, Calif., July 31, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on July 30…
IDE892 is a potential best-in-class PRMT5 inhibitor with 1,400-fold selective MTA-PRMT5 cooperative binding vs SAM-PRMT5 cooperative binding, and CYP3A4 IC50 greater than 45 micromolar with no time-dependent inhibition of the 7 major cytoc…
SOUTH SAN FRANCISCO, Calif., July 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced three abstract presentations at the 2026 European Society of Medical Oncolog…
SOUTH SAN FRANCISCO, Calif., June 26, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on June 25…
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, on Tuesday announced the appointment of Yujiro S. Hata as Chairman of the Board by its Board of Directors. Hata currently serves as the President and Chief Exe…
SOUTH SAN FRANCISCO, Calif., June 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, today announced that its Board of Directors has elected Yujiro S. Hata, Chairman of the Boar…
IDE892 is a potential best-in-class MTA-Cooperative PRMT5 combination partner with MAT2A and pan-RAS inhibitors, with favorable drug-like properties IDE892 has a CYP3A4 IC50 greater than 45 micromolar, and did not show time dependent inhib…
IDEAYA Biosciences Inc. (NASDAQ:IDYA) is one of the 10 best AI driven biotech stocks to invest in. On June 3, in order to study the safety and efficacy of IDE892 in conjunction with Roche’s pan-RAS inhibitor, RG6505, in patients with MTAP-…
SOUTH SAN FRANCISCO, Calif., June 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the closing of its underwritten public offering of 7,222,225 shares of its common stock at a public offering price of $27.00…
Boston-headquartered Tango Therapeutics (TNGX) stock surged on Monday, driven by encouraging results from a pancreatic cancer trial. TNGX is a clinical-stage biotech firm focused on discovering and delivering next-gen precision cancer medi…
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.4% and the actively trad PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
[glowing graph 2] Jonathan Kitchen Stock futures rose slightly, and crude oil benchmark prices fell on Tuesday morning as geopolitical anxieties showed signs of easing. Here are some of Tuesday's biggest stock movers: BIGGEST STOCK GAINERS…
(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), a clinical-stage oncology company, announced the pricing of an underwritten public offering of 5.56 million shares at an offering price of $27.00 per share and pre-funded warrants to purchase up…
(RTTNews) - Today's top gainers include Tango Therapeutics, following encouraging pancreatic cancer trial data; Aspire Biopharma, ahead of upcoming milestones; Alvotech, after FDA acceptance of its interchangeable biosimilar to Entyvio for…
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of an underwritten public offering of common stock and pre-funded warrants. IDEAYA is selling 5,555,556 shares of…
SOUTH SAN FRANCISCO, Calif., June 8, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced that it intends to offer and sell up to $300.0 million of shares of its common stock and, in lieu of common stock, to offer a…
IDEAYA Biosciences recently reported full Phase 2/3 OptimUM-02 data showing its darovasertib and crizotinib combination improved progression-free survival and response rates versus standard therapies in first-line HLA*A2:01 negative metast…
[Pancreatic cancer is cancer that forms in the cells of the pancreas. 3d illustration] * IDEAYA Bioscience (IDYA [https://seekingalpha.com/symbol/IDYA]) and Roche (RHHBY [https://seekingalpha.com/symbol/RHHBY]) have agreed to jointly evalu…
IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-RAS inhibitor, in MTAP-deleted, RAS-mutan…
Darovasertib combination resulted in a statistically significant and clinically meaningful improvement in median PFS vs. investigator's choice of therapy (ICT) – 6.9 months vs. 3.1 months, HR: 0.42, 58% reduction in risk of disease progres…
SOUTH SAN FRANCISCO, Calif., May 29, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on May 28,…